Intelligent Bio Solutions earnings release, August 19, 2026

Intelligent Bio Solutions Inc. (INBS) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Intelligent

Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge

Growth

Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units

Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year

502 active customers as of June 30, 2026, reflecting continued commercial momentum across safety-critical industries

Company made substantial progress toward FDA clearance and planned market expansion during the year

NEW

YORK, August 19, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the full year ended June 30, 2026, and provided a business update.

“Fiscal

2026 was a year of clear, compounding progress across every aspect of our business,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “We delivered record annual revenue of $4.2 million, a 38% increase year-over-year, driven by a 22% expansion in our reader installed base and a 35% increase in consumable cartridges. Our razor-razorblade model is gaining scale, with hardware placements generating the installed base and growing consumable utilization delivering recurring revenue. Entering fiscal

2027, we are focused on three priorities: sustaining the operational improvements driving gross margin expansion, continuing to accelerate commercial growth, and advancing our FDA regulatory program toward planned U.S. market entry. To that end, we have completed all clinical data collection across our FDA 510(k) clinical study program. Analysis of collected data is underway, and we remain on track for our

FDA submission.”

“The financial results for fiscal 2026 reflect a business that is scaling with improving unit economics,” said Spiro Sakiris, CFO at Intelligent Bio Solutions. “Full-year gross profit grew 64% to $2.05 million and gross margin expanded 778 basis points to

48.63%. These improvements are a result of our transition to Syrma Johari as a high-quality, lower-cost manufacturing partner, an optimized product mix weighted toward higher-margin cartridge consumables, and the operational leverage that comes from growing volumes across a more efficient production base. Our sustained investment in marketing, sales, product awareness, and customer support has been the direct commercial driver behind our 38% revenue growth and the expanding utilization we are seeing across our installed base.”

Full

Year Fiscal 2026 Financial Highlights

Progress

Toward FDA Clearance and U.S. Market Expansion

INBS made substantial progress throughout fiscal 2026 in advancing its FDA 510(k) submission, supporting its planned entry into the multi-billion-dollar

U.S. drug screening market beyond current Forensic Use Only settings. The Company’s regulatory program accelerated significantly, underpinned by a series of clinical and technical studies:

Commercial

Growth and Market Expansion

INBS continued to expand its commercial presence across international markets throughout fiscal 2026, supported by targeted investment in marketing, sales, and customer support infrastructure.

Operational

Efficiencies Strengthening Business Fundamentals

The improvement in gross profit margin from 40.85% to 48.63% year-over-year reflects the structural progress INBS has made in its production and commercial operations throughout fiscal 2026:

About

Intelligent Bio Solutions Inc.

Intelligent

Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The

Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.

With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: https://ibs.inc/

Forward-Looking

Statements

Financial statements

Income Statement

Year ended June 30, — Consolidated Statements of Operations and Other Comprehensive Income (Loss)

Year ended June 30, – 2026Year ended June 30, – 2025
Revenue4,215,1753,052,532
Cost of revenue (exclusive of amortization shown separately below)-2,165,181-1,805,673
Gross profit2,049,9941,246,859
Other incomeGovernment support income677,776816,901
Operating expensesSelling, general and administrative expenses-10,502,161-8,918,468
Operating expensesDevelopment and regulatory approval expenses-3,371,292-2,396,513
Operating expensesDepreciation and amortization-1,163,847-1,207,875
Operating expensesImpairment of long-lived assets-298,555-220,062
Operating expensesTotal operating expenses-15,335,855-12,742,918
Operating expensesLoss from operations-12,608,085-10,679,158
Other income (expense), netInterest expense-10,736-26,339
Other income (expense), netRealized foreign exchange gain (loss)39,820-911
Other income (expense), netInterest income110,329101,522
Other income (expense), netTotal other income, net139,41374,272
Other income (expense), netNet loss-12,468,672-10,604,886
Other income (expense), netNet loss attributable to non-controlling interest-37,697-36,153
Other income (expense), netNet loss attributable to Intelligent Bio Solutions Inc.-12,430,975-10,568,733
Other comprehensive (loss) incomeForeign currency translation (loss) gain-218,242384,670
Other comprehensive (loss) incomeTotal other comprehensive (loss) income-218,242384,670
Other comprehensive (loss) incomeComprehensive loss-12,686,914-10,220,216
Other comprehensive (loss) incomeComprehensive loss attributable to non-controlling interest-37,697-36,153
Other comprehensive (loss) incomeComprehensive loss attributable to Intelligent Bio Solutions Inc.-12,649,217-10,184,063
Other comprehensive (loss) incomeNet loss per share, basic and diluted*-8.44-20.04
Other comprehensive (loss) incomeWeighted average shares outstanding, basic and diluted*1,472,744527,364

Balance Sheet

As of June 30, — Consolidated Balance Sheets

As of June 30, – 2026As of June 30, – 2025
Current assetsCash and cash equivalents3,992,3121,019,909
Current assetsAccounts receivable, net848,464594,614
Current assetsInventories, net418,577635,215
Current assetsResearch and development tax incentive receivable806,951734,408
Current assetsAssets held for sale327,500
Current assetsPrepaid expenses and other current assets1,030,932826,976
Current assetsTotal current assets7,097,2364,138,622
Current assetsProperty and equipment, net294,399251,325
Current assetsOperating lease right-of-use assets1,751,04069,520
Current assetsIntangibles, net2,799,1613,790,319
Current assetsTotal assets11,941,8368,249,786
Current liabilitiesAccounts payable and accrued expenses4,130,2134,534,246
Current liabilitiesCurrent portion of operating lease liabilities147,00584,659
Current liabilitiesCurrent employee benefit liabilities651,706534,990
Current liabilitiesNotes payable197,146
Current liabilitiesTotal current liabilities4,928,9245,351,041
Current liabilitiesEmployee benefit liabilities, less current portion49,93184,921
Current liabilitiesOperating lease liabilities, less current portion1,672,155
Current liabilitiesTotal liabilities6,651,0105,435,962
Shareholders’ equityCommon stock, $0.01 par value, 100,000,000 shares authorized, 2,905,615 and 2,905,603 shares issued and outstanding, as of June 30, 2026, respectively; 732,339 and 732,327 shares issued and outstanding, as of June 30, 2025, respectively*29,0567,324
Shareholders’ equityTreasury stock, at cost, 12 shares as of June 30, 2026 and 2025, respectively*-1-1
Shareholders’ equityAdditional paid-in capital*80,992,00665,849,822
Shareholders’ equityAccumulated deficit-74,964,040-62,533,065
Shareholders’ equityAccumulated other comprehensive loss-546,186-327,944
Shareholders’ equityTotal consolidated Intelligent Bio Solutions Inc. equity5,510,8352,996,136
Shareholders’ equityNon-controlling interest-220,009-182,312
Shareholders’ equityTotal shareholders’ equity5,290,8262,813,824
Shareholders’ equityTOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY11,941,8368,249,786
Full release

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section

21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties.

Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, secure regulatory clearance or approvals, and timelines to enter the U.S. market, among others. Although Intelligent

Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,”

“plans,” “projects,” “intends,” “potential,” “may,” “could,”

“might,” “will,” “should,” and “approximately,” or other words that convey uncertainty... (truncated)rd-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the

U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release.

Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company

Contact

Intelligent

Bio Solutions Inc. info@ibs.inc

Investor

& Media Contact

Valter

Pinto, Managing Director

KCSA

Strategic Communications

PH:

(212) 896-1254

INBS@kcsa.com — Financial tables to follow — Intelligent

Bio Solutions Inc.

Consolidated

Balance Sheets

Intelligent

Bio Solutions Inc.

Consolidated

Statements of Operations and Other Comprehensive Income (Loss)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Intelligent Bio Solutions earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.